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1. Introduction
Gliomas encompass approximately 80% of primary brain malignancies [1]. The five-year
survival rate is dependent on the subtype of glioma. According to the Central Brain Tumor
Registry there are about 13,000 deaths and 18,000 new cases per year of primary brain cancer
in the United States and the overall average annual age-adjusted incidence rate for 2006-2010
for primary brain and CNS tumors was 21.03 per 100,000 [2]. In this chapter, our main focus
is glioblastoma (GBM), which is by far the most common and the most malignant of all primary
brain tumor [2]. Often described as the most lethal or the most devastating brain tumors,
gliomas continue to carry a very poor prognosis at all levels, quantity and quality of life. GBM
almost exclusively recurs despite meticulous conventional therapies, including surgical
resection, radiation, and chemotherapy and bevacizumab. Despite all advances, the survival
rates continue to be low, with a median survival of approximately 15 months in patients with
malignant gliomas [3].
The multiple hit theory of cancer speculates that the origin and progression of GBM is the
product of complex series of molecular processes like activation of oncogenes and alterations
in tumor suppression genes. However, the complexity of the molecular interactions in
malignant gliomas imposes a great challenge that indeed has crucial implications on treatment.
This cannot be achieved without a meticulous understanding of this multifaceted process and
its molecular mechanism, and therefore dictates dissection at systems level. The Cancer
Genome Atlas Research Network has sequenced the genome of GBM and deduced that the
apparatus of tumor growth and recurrence is the result of complex epigenetic mechanisms
and gene interactions [4]. The twenty first century has been referred to as the genomic
millennium, thus in an era where genes dictate remedy a comprehensive understanding of the
systems biology of gliomas may be a key to the cure. Our goal in this chapter is to touch on
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the complexity of the molecular networks of GBM by presenting on an overview without
delving into details. We will focus on how molecules and pathways are dysregulated in GBM
rather than presenting detailed graphs of networks as the latter are readily easily found. To
illustrate the clinical relevance of a systems approach to molecular networks, we dissect the
case of the use of rapamycin in a GBM clinical trial and discuss the pathogenesis of its adverse
effect in causing activation of AKT, an oncogene.
2. Classes of GBM
Malignant gliomas develop as part of a multistep process comprising chronological and
collective genetic modifications resulting from core and environmental dynamics. Cowden,
Turcot, Li-Fraumeni, neurofibromatosis type 1 and type 2, tuberous sclerosis, and familial
schwannomatosis are among the predisposing syndromes for glioblastoma occurrence [15].
From a molecular perspective, malignant gliomas are greatly heterogeneous tumors [14]. In a
nutshell, 4 transcriptional subclasses of GBM have been proposed: classical, mesenchymal,
proneural, and neural [1]. The classical type glioblastoma typically exhibits chromosome 7
amplifications, chromosome 10 deletions, EGFR amplification, EGFR mutations (point and vIII
mutations), and Ink4a/ARF locus deletion. The mesenchymal subclass shows a high frequency
of NF1 mutation/deletion and high expression of CHI3L1, MET, and genes involved in tumor
necrosis factor and nuclear factor–κB pathways. Proneural type glioblastoma is characterized
by changes of PDGFRA and mutations in IDH1 and TP53; these are features common to lower-
grade gliomas and secondary GBM. A characteristic feature of the neural subclass of GBM is
the expression of neuronal markers.
3. Gliomagenesis
The multiple hit theory of cancer stipulates sequential molecular events leading to GBM. The
following is a summary of current ideas. One of the first steps in tumoregenesis is loss of cell
cycle control. The cell cycle checkpoint that has been of most interest is the G1-S phase. This
important checkpoint is mainly controlled by p16INK4a/cyclin-dependent kinase (CDK)-4/RB
(retinoblastoma) 1 pathway, which involves p16, CDK-4, cyclin D1, and RB1[16]. The CDK/
cyclin D1 complex phosphorylates RB1 therefore releasing the E2F transcription factor, which
in turn activates the genes, involved in the G1/S transition [17]. Subsequent steps in glioma‐
genesis include the overexpression of growth factors and their receptors. A diverse array of
growth factors such as epidermal growth factor receptor (EGFR), platelet-derived growth
factor (PDGF), basic fibroblast growth factor (bFGF, FGF-2), transforming growth factor (TGF)-
alpha, and insulin-like growth factor (IGF)-1 are overly expressed in glioblastoma [18, 19].
Malignant gliomas are highly vascular tumors; the angiogenic molecule that has been most
widely implicated in GBM is vascular endothelial growth factor (VEGF), an endothelial cell
mitogenic [20].
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Another key event contributing to gliomagenesis is the abolishment of apoptosis, or program‐
med cell death. Malignant glioma cells, not only divide uncontrollably, but also intentionally
lose the ability to undergo apoptosis. p53, a key molecule involved in apoptosis, is often
mutated during gliomagenesis [21]. An important process contributing to gliomagenesis is
genetic instability, which refers to the property that random mutations are introduced in
dividing cancer cells because of the loss of check points and the molecular machinery that
ensures that the genome is copied faithfully during mitosis [22]. A clinical correlation to genetic
instability is the Turcot syndrome [23].
4. Signaling pathways
A large number of signaling pathways exchange information to generate a large molecular
network that controls the phenotypes of GBM. A detailed discussion is beyond the scope of
this chapter. In this section, we will discuss how the RTK/PI3K/Akt, mTOR, Ras/MEK/MAPK,
p53, ATM/Chk2, Rb, and stat3 pathways are affected to GBM. Additional pathways will be
briefly discussed in the section on crosstalk.
4.1. RTK/PI3K/Akt pathway
This pathway regulates a range of cellular processes such as proliferation, growth, apoptosis,
and cytoskeletal rearrangement. It involves receptor tyrosine kinases (RTKs), like EGFR,
PDGFR, and VEGFR, as well as tumor suppressor protein phosphatase (PTEN), and protein
kinases PI3K, AKT. Irregular activation of RTK/PI3K/AKT is commonly seen in malignant
gliomas [24].
4.1.1. Receptor tyrosine kinases
RTKs relay extracellular signals to activation of intracellular networks through PI3K and AKT.
EGFR gene amplification is the most widespread alteration present in GBM [25]. The most
common is EGFR vIII, which relays ligand independent accumulative growth signals [26, 27].
Some studies have previously shown a correlation between aberrance of EGFR and aggres‐
siveness of tumor and therefore shorter survival [28, 29]. Unfortunately, EGFR inhibitors such
as Gefinitib and Erlotinib have not produced promising results in clinical trials of patients with
GBM [30, 31]. Overexpression of PDGFR (especially PDGFR-α) and PDGF have been docu‐
mented in astrocytic tumors irrespective of the grade [32], [33]. PDGFRA amplification and
IDH1 mutation are a characteristic of the proneural subtype of GBM implying a possible
association of the proneural subtype and secondary GBM [4]. Anti-PDGFR therapy such as
imatinib has not been promising either [34].
4.1.2. PI3K–PTEN-AKT signaling
AKT, a serine/threonine kinase that acts to regulate cell growth, proliferation, and apoptosis,
is activated in about 80% of human GBMs [35]. PI3K belongs to the family of lipid kinases.
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PI3K enzymes produce phosphatidylinositol-3,4,5-trisphosphate (PIP3), a lipid secondary
messenger, which is found to be at high levels in cancer cells [36, 37]. Binding of PI3Ks to RTKs
results in activation of AKT through PiP3 and PDK1 [38]. Dissecting the PI3K complex, it is
composed of a catalytically active protein, p110α, encoded by PIK3CA, and a regulatory
protein, p85α, encoded by PIK3R1. In primary GBM, PIK3CA mutations and amplification are
seen in about 5% to 13% of cases [39]. Furthermore, PIK3R1 mutations have been reported in
about 10 % in GBM patients [4].
PTEN (phosphatase and tensin homologue, located on chromosome 10) is a tumor suppressor
gene. PTEN mutations are associated with several types of cancer including GBM. Loss of
heterozygosity of chromosome 10, which causes deletions or mutations of PTEN, is a common
event in GBMs. PTEN negatively regulates the PI3K/AKT/PKB pathway by blocking AKT
signaling via the reduction of intracellular levels of PIP3. Furthermore, lower PTEN activity
induces activation of the RTKs/PI3K/AKT pathway. This is due to the negative inhibition
accomplished by PTEN antagonizing PIK3 [40]. GBMs typically harbor diminished expression
of PTEN through homozygous deletion or mutations of PTEN, which contributes the activation
of the RTKs/PI3K/Akt pathway [4, 41, 42]. Mesenchymal and classical types of GBM exhibit
loss of PTEN (www.cbtrus.org). It is noteworthy that GBM cells expressing EGFRvIII with an
intact PTEN appear to have a higher response rate to EGFR inhibitors [35, 43].
4.2. mTOR
Signaling through mTOR is mediated by two independent complexes, mTORC1 and mTORC2.
mTORC2 is activated by growth factors and ribosomes and in turn activates AKT among other
kinases via phosphorylation [44]. mTORC1 controls cellular metabolism, biosynthesis, stress,
and by several growth factors such as EGF and its receptor, EGFR [45]. In settings promoting
cell growth, mTORC1 phosphorylates substrates to stimulate anabolic processes such as
ribosome biogenesis, translation, and synthesis of lipids and nucleotides and to abolish
catabolic processes such as autophagy [45]. Likewise, mTORC2 promotes cancer growth by
stimulating glucose uptake via activation of AKT and activating serum/glucocorticoid
regulated kinase (SGK), which contributes to proliferation and survival [46]. Inhibitors of
mTOR, like rapamycin, sirolimus, temsirolimus, everolimus have not shown efficacy in GBM
[47, 48]. In fact, inhibitors of mTOR lead to elevated expression and activity of growth factor
receptors, which increases PI3K activity and RAS signaling. Below we discuss the effects of
rapamycin on the mTOR pathway in detail.
4.3. Ras/MAPK pathway
The 3 components of the human Ras genes (Rat Sarcoma) are transmuting oncogenes and
include: H-Ras, N-Ras, and K-Ras. Ras is a member of the G protein family, which basically
means that it is activated by binding to guanosine triphosphate (GTP), and deactivated by
binding to guanosine diphosphate (GDP) [49]. Ras serves to activate serine tyrosine kinases
(STK) including Raf, MAPK (ERK1 and ERK2), PI3K, among other proteins that influence cell
proliferation, differentiation, and survival [50]. Although the mutual activation of Ras and
AKT in neural progenitors contributes to gliomagenesis in mouse models [51], Ras mutations
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are uncommon in human GBM [4]. Activated Raf phosphorylates and activates MAPK kinase
(MAPKK), also called MEK, which in turn phosphorylates and activates MAPK [52, 53][54],
which then moves to the nucleus to induce other transcription factors including Elk1, c-myc,
Ets, STAT (signal transducers and activators of transcription), and PPARγ (peroxisome
proliferator-activated receptor γ), which induce cell cycle progression and anti-apoptosis
genes [50, 55].
NF-1, a tumor suppressor gene encoding neurofibromin, negatively regulates Ras and
influences adenylate cyclase- and AKT-mTOR-mediated pathways [56]. NF-1 mutation and
homozygous deletions are detected in 18% of GBM [4]. Mesenchymal type GBM appears to
respond to concomitant chemo-radiation therapy and happens to commonly have inactivation
of the NF-1 (37%), p53 (32%), and PTEN genes [57].
4.4. The p53 pathway
The p53 gene, labeled as the "guardian of the genome", is located at chromosome 17q13.1 and
encodes a protein that takes action against miscellaneous cellular stresses to regulate the
corresponding genes that provoke programmed cell death or apoptosis, cell differentiation,
senescence, DNA repair, and neovascularization [58]. The p53 pathway is the most frequently
mutated pathway in human cancer and is essentially disrupted in roughly 80% of high-grade
gliomas. p53, activated in response to DNA damage, induces transcription of genes such as
p21Waf1/Cip1 that arrest the cell cycle progression at the G1 phase [59].
An important regulator of the p53 pathway is MDM2, an E3 ubiquitin ligase that negatively
modulates p53 through transcriptional inhibition by direct binding as well as by degradation
through its E3 ligase activity [60] [61]. On the other hand, the transcription of the MDM2 gene
is induced by wild-type p53 [62]. This creates an autoregulatory feedback loop which controls
the function of both the expression of MDM2 and the activity of p53. Another regulator of the
p53 pathway is the tumor suppressor protein ARF (p14ARF), which controls p53 transcrip‐
tional activities by binding to MDM2 and consequently hindering its E3 ubiquitin ligase
activity [63, 64]; conversely p14ARF expression is negatively regulated by p53 [59]. Both low
grade and high grade gliomas exhibit inactivation or mutation of p14ARF [65]; homozygous
deletion of p16INK4a/p14ARF/p15INK4b locus is one of the common mutations in GBMs [66].
Remarkably, mouse models revealed that co-deletion of ARF and INK4a increased accordingly
with tumor progression from low- to high-grade gliomas [67]. This suggests that ARF and
INK4a mutations are important steps in gliomagenesis.
4.5. ATM/Chk2 pathway
Disruption of the ATM/Chk2 pathway increases the speed of growth and development of
glioma [68]; it also contributes to resistance to radiation therapy by helping the malignant cell
activate a group of sensor kinases including ATM, ATR, and DNA-dependent protein kinase
[69]. The latter phosphorylates multiple downstream mediators such as checkpoint kinases
Chk1 and Chk2 that lead to cell-cycle checkpoint initiation and/or apoptosis [70]. Chk2,
encoded at chromosome 22q12.1, acts as a tumor suppressor as it regulates p53-dependent
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apoptosis [71]. Chk2 mutations have in general been rarely reported; however single copy loss
of the chromosomal region containing Chk2 has been reported in gliomas [4].
4.6. Rb pathway
The retinoblastoma gene, Rb, is implicated in progression from low grade to higher grade
astrocytoma [72], and it is inactivated in GBM [73]. The Rb pathway suppresses cell cycle entry
and progression and curbs the p53 pathway by binding and inhibiting transcription factors of
the E2F family. Of note, Rb controls progression from G1 to S-phase of the cell cycle [16]. Rb
is regulated by the complex of cyclin-dependent kinases (CDKs); in the G1 phase, Rb is
normally inactivated by Cyclin D/CDK4/CDK6- induced phosphorylation, causing its release
from E2F and consequent cell cycle progression into the S phase. CDKN2B, a CDK inhibitor,
which is commonly inactivated in GBM, forms a complex with CDK4 or CDK6, thus preventing
the activation of CDKs. The outcome of this inhibition is prevention of cell growth. In addition
to the inactivation of CDKN2B, amplification of CDK4 and CDK6 is also common in GBM,
demonstrating that both CDK4 and CDK6 have a fundamental function in gliomagenesis and
progression [74]. The CDKN2A (p16INK4a) protein binds to CDK4 and inhibits the CDK4/
cyclin D1 complex, consequently inhibiting cell cycle transition from G1 to S phase [73]. This
implies that any alteration of Rb, CDK4, or CDKN2A causes aberrant dysregulation of the G1-
S phase transition. Complete loss of Rb, homozygous deletion or mutation of CDKN2A, CDK4
amplification, CDKN2B (p15INK4b) homozygous deletion, CDKN2C (p18INK4c) homozy‐
gous deletion, CCND2 (cyclin D2) amplification, and CDK6 amplification are observed in
almost 80% of GBM [75-77].
4.7. STAT3
STAT (Signal transducers and activators of transcription) complexes are a family of cytoplas‐
mic proteins that have SH2 (Src Homology-2) domains functioning as transcription factors that
control cellular responses to cytokines and growth factors by signal transduction from the
plasma membrane to the nucleus [78]. Target genes are then transcribed and contribute to
proliferation, invasion, and apoptosis. STAT3 is an example of the STAT family proteins; it is
rendered active by EGF and is overexpressed in GBM [79]. STAT3 also plays a role in the
development of neural stem cells and astrocytes [80]. Targeting STAT3 may influence glioma
cell motility, resistance to temozolomide, as well as clinical outcome [81-83].
5. Crosstalk
A distinguished characteristic of signaling networks in GBM is the presence of crosstalk, or
communication between subnetworks, which interact to promote gliomagenesis and all the
phenotypes of GBM. For example, there is evidence of mutual cross talk between cells
inactivation of either Ras/Raf/MAPK or PI3K/AKT/mTOR triggering activation of the other
[39]. Other examples are the interactions between Ras and stem cell factor (SCF)/c-kit signaling,
mTOR, and MAP kinase pathways and the interactions between PI3Kand STAT3 pathways
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and NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells, in gliomas [84] [85].
In this section, we examine selected networks that play a role in glioma stem cells (GSC) and
cell motility.
5.1. GSC
GSC have the particular ability to auto-renew and initiate gliomagenesis, express neural stem
cell markers, and differentiate into multiple phenotypes such as neuronal, astrocytic, and
oligodendroglial. Sonic hedgehog homolog (SHH) and Notch are overly expressed in GSC and
therefore aberrantly regulate neural progenitor cells [86]. SHH is an important mitogen for
medulloblastoma precursor cells. The SHH pathway also contributes to glioma formation as
it is activated in GSCs. The SHH pathway is also closely related to the cell cycle as it inactivates
Rb and causes over-expression of cell cycle regulators such as N-myc. PDGF signaling in neural
stem cells is required for oligodendrogenesis, and amplification of this signal causes an
abnormal proliferation of neural stem cells and the formation of large glioma-like lesions [87].
Notch (Notch1-4 in mammals) is a family of transmembrane receptors that control intercellular
signaling [88]. They are transmembrane proteins that bind to notch and reveal the receptor to
proteolytic activation. Notch is cleaved by presenilin 1 which generates a Notch1 intracellular
domain (NICD), a nuclear transcriptional activator. Notch activation induces expression of
downstream target genes, such as p53, and promotes neural stem cell growth [89]. BMPs are
growth factors that act through binding to cell-surface receptor kinases (BMPRs); the effectors
of BMPRs are the Smad proteins, which play a major role in bone and cartilage formation. The
overall activity of BMPs is regulation of transcription. BMP ligands exhaust the GSC popula‐
tion by inducing the differentiation of GSCs into astroglial and neuron-like cells. Treating GSCs
with BMPs in vivo delays tumor growth and diminishes tumor invasion [90].
miRNA is a small non-coding RNA that post-transcriptionally downregulates gene expression.
Several studies have identified aberrant miRNA (microRNA-21, miR-326, microRNA-34a)
expression in gliomas, and linked some of them to GSC maintenance and growth [91, 92].
Finally, Tumor Necrosis Factor alpha-Induced Protein (TNFAIP) 3 regulates both the NF-κB
pathway as well as GSC self-renewal, growth, and apoptotic resistance [93].
5.2. Brain invasion and motility
Brain invasion is a hallmark of gliomas. Tumor cell migration requires highly coordinated
steps of dissociation of existing cellular adhesions, remodeling of the actin cytoskeleton to
project lamellipodium extensions, formation of new adhesions, and tail detachment along with
proteolytic processing and secretion of extracellular matrix proteins along the trajectory. This
complex phenotype requires crosstalk between networks that control the extracellular matrix,
growth factors, cdc42, GTPases, actin polymerization, PAK, src, cadherins, PIP3, integrins, and
myosin (see [96] for details).
Furthermore, some GBM exhibit enhanced motility at 5% ambient oxygen, which is higher
than the typical 0.3-1% concentrations observed in cancer hypoxia. This result supports an
increased propensity for invasion. The phenotype of increased motility in low ambient oxygen
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conditions is mediated by phosphorylation of src, which in turn phosphorylates NWASP,
Neural Wiskott-Aldrich Syndrome Protein (see [97] for details).
6. Effects of rapamycin on AKT
In the preceding section we have highlighted the complexity of the molecular interactions in
GBM and the large number of subnetworks that communicate to generate the phenotypes.
Because rapamycin inhibits the mTOR complex, it was considered a hopeful prospect for
pharmaceutical therapy. However, in a clinical trial using rapamycin in the treatment of PTEN-
deficient GBM, researchers encountered a paradoxical increase in AKT signaling, which was
unexpected and undesirable as the latter promotes oncogenic processes [98]. The exact
mechanisms for this finding are not yet known. Although many scientists postulate about a
simple loss of negative feedback, there may be more than what meets the eye. To illustrate this
point, we will delineate a well-characterized pathway in GBM molecular biology and discuss
how intersecting activation and inhibitory pathways can lead to paradoxical downstream
effects.
As reviewed in Howell et al. and Huang and Manning, mTORC1 acts ultimately as a negative
regulator of AKT through various mechanisms [99-101]. First, mTORC1 directly phosphory‐
lates IRS (insulin receptor substrate), which is thought to hinder the scaffolding ability of PI3K
to activate AKT. Additionally, mTORC1 acts through its downstream effector S6K1 (S6 kinase
1), which also phosphorylates IRS at specific serine residues and reduces downstream AKT
activation [102-105]. Zhang et al. in 2003 and 2007 showed that mTORC1 activation leads to
repression of PDGFR A and B transcription, which inhibits PDGF signaling to AKT and blocks
proper transmission of signals from other growth factors [106, 107]. AKT also acts as an
activator of mTORC1; but this interaction is irrelevant to our discussion of mTORC1 inhibitors
because direct inhibitors of mTORC1 are not influenced by AKT.
Since mTORC1 inhibits AKT (Figure 1, t = 0), bringing down mTORC1 via rapamycin (Figure
1, t = 1) would subsequently lead to an increase in AKT (Figure 1, t = 2).
Figure 1. Cartoon depicting the negative effects of mTORC1 on AKT activation and its response to perturbations.
Blocked arrows indicate repression/deactivation. The arrow pointing down indicates repression of mTORC1 activity at
time = 1. The arrow pointing up indicates the response of the network by increasing the activity of AKT at time = 2.
At first sight this explanation is logical, but when we look deeper into the networks we discover
additional factors to this relationship that can provide alternate explanations for the clinical
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trial’s findings. The simple diagram of Figure 1a does not appear to be the appropriate
explanation.
Subsequent studies have found that at low concentrations, rapamycin treatment leads to an
increase in AKT activity; however, at high, super-physiological concentrations rapamycin
causes a decrease in AKT activity [108]. Interestingly, at high concentrations of rapamycin,
both mTORC1 and mTORC2 are inhibited. Hence, we need to consider the effects of mTORC2
on AKT. In fact, mTORC2 phosphorylates AKT on S473 (serine 473), which activates AKT at
the plasma membrane [112]. The observation, that inhibiting both mTORC1 and mTORC2
caused a decrease in AKT activity, indicates that mTORC1 is a weak inhibitor of AKT as
compared to mTORC2 as an activator (see Figure 2 for details).
Figure 2. Cartoon depicting relative effects of mTORC1 and mTORC2 on AKT and the response of the network to
high concentrations of rapamycin. Blocked and regular arrows indicate repression/deactivation and activation, re‐
spectively. The thickness of the arrows reflects the level of repression or activation. If mTORC2 is a stronger activator
of AKT than mTORC1 is a repressor (time = 0), treating the cells with high concentrations of rapamycin, which inhibits
both mTORC1 and mTORC2 (time = 1), causes a decrease in AKT activity (time = 2).
If we delve deeper into these pathways, we learn of a negative loop between AKT, TSC2
(tuberous sclerosis complex 2), and mTORC2 (See Figure 3) [101]. AKT directly inhibits the
activity of the TSC2 complex by phosphorylating TSC2 [109-111]. Furthermore, Huang and
Manning provide evidence for the subsequent arm of the loop where the TSC2 complex
activates mTORC2 in a manner independent of mTORC1 [100]. These relationships together
comprise the negative loop illustrated in Figure 3.
We assume that the physiological levels of rapamycin used in the clinical trial inhibit the
activity of mTORC1 without any effects on mTORC2; let us now study the reaction of the
network in the presence of the AKT/TSC2/mTORC2 negative loop (see Figure 4). Theoretically,
if mTORC1 levels go down (Figure 4a), AKT activity should initially increase (Figure 4b).
However, higher AKT activity would lead to augmented inhibition of the TSC2 complex
(Figure 4c). The lower levels of TSC2 complex would then reduce the activation of mTORC2
(Figure 4c), which in turn feeds back to influence AKT. The ultimate result on AKT depends
on the dynamics and the strengths of the connections the negative loop. At this stage, two
possibilities arise as follows.
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Figure 4. Cartoon depicting the reaction of the network to rapamycin in the presence of the negative loop. Blocked
and regular arrows indicate repression/deactivation and activation, respectively. Arrows pointing up or down indicate
perturbations causing increased or decreased activity, respectively.
Possibility A: If both AKT’s inhibitory effect on TSC2 and TSC2’s activation effect on mTORC2
are strong, then an increase in AKT will lead to a significant decrease in mTORC2. Because the
Figure 3. Cartoon depicting negative loop between AKT, mTORC2 and the TSC2 complex. Blocked and regular ar‐
rows indicate repression/deactivation and activation, respectively.
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latter is a stronger activator than mTORC1 is a repressor (Figure 3), this causes an ultimate
decrease in AKT activity (Figure 4e).
Possibility B: The negative loop would cause a decrease in mTORC2 activity in any case. This
could attenuate but may not reverse the increase in AKT (Figure 4f).
This exercise highlights the profound effects of the presence of a negative loop in the simple
network. The results of the clinical trial where rapamycin leads to an increase in AKT activity
would be consistent with the explanation of possibility B. However, possibility A cannot be
excluded, since other regulatory loops likely influence this pathway as well. In creating
treatments and therapeutic strategies in GBM, it is imperative to gain a complete picture of the
complexity of intersecting pathways since inhibition can lead to paradoxical, sometimes
detrimental results.
7. Conclusion
The molecular networks of GBM include a large number of molecules and interactions, as well
as multiple subnetworks and crosstalk. These large networks appear to have the ability to not
only bypass therapeutic blockade, but to react to therapeutic modalities by activation of
oncogenic subnetworks. We are not surprised that little progress has been made against these
deadly and intelligent tumors. Success requires a clear understanding of these large networks
as well as predictions of their dynamical (time-dependent) behavior in response to perturba‐
tions (ie. therapeutic interventions). Fortunately, recent advancements in genomics and
mathematical biology bring us closer to attaining these goals.
Author details
Caroline Agha, Hannah C. Machemehl and Hassan M. Fathallah-Shaykh*
*Address all correspondence to: hfathall@uab.edu
The University of Alabama at Birmingham, Department of Neurology, USA
References
[1] Phillips, H.S., et al., Molecular subclasses of high-grade glioma predict prognosis, delineate
a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 2006.
9(3): p. 157-73.
Systems Biology of Glioblastoma Multiforme
http://dx.doi.org/10.5772/59642
39
[2] Ostrom, Q.T., et al., CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2006-2010. Neuro Oncol, 2013. 15 Suppl 2: p.
ii1-56.
[3] Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblasto‐
ma. N Engl J Med, 2005. 352(10): p. 987-96.
[4] Cancer Genome Atlas Research, N., Comprehensive genomic characterization defines hu‐
man glioblastoma genes and core pathways. Nature, 2008. 455(7216): p. 1061-8.
[5] Temple, S., The development of neural stem cells. Nature, 2001. 414(6859): p. 112-7.
[6] Kriegstein, A. and A. Alvarez-Buylla, The glial nature of embryonic and adult neural stem
cells. Annu Rev Neurosci, 2009. 32: p. 149-84.
[7] Richardson, P.M., Ciliary neurotrophic factor: a review. Pharmacol Ther, 1994. 63(2): p.
187-98.
[8] Kornblum, H.I., et al., Multiple trophic actions of heparin-binding epidermal growth factor
(HB-EGF) in the central nervous system. Eur J Neurosci, 1999. 11(9): p. 3236-46.
[9] Powell, E.M., et al., Mechanisms of astrocyte-directed neurite guidance. Cell Tissue Res,
1997. 290(2): p. 385-93.
[10] van den Pol, A.N. and D.D. Spencer, Differential neurite growth on astrocyte substrates:
interspecies facilitation in green fluorescent protein-transfected rat and human neurons.
Neuroscience, 2000. 95(2): p. 603-16.
[11] Komuro, H. and P. Rakic, Distinct modes of neuronal migration in different domains of de‐
veloping cerebellar cortex. J Neurosci, 1998. 18(4): p. 1478-90.
[12] Bacci, A., et al., The role of glial cells in synaptic function. Philos Trans R Soc Lond B Biol
Sci, 1999. 354(1381): p. 403-9.
[13] Rasheed, B.K., et al., Molecular pathogenesis of malignant gliomas. Curr Opin Oncol,
1999. 11(3): p. 162-7.
[14] Theeler, B.J., et al., Moving toward molecular classification of diffuse gliomas in adults.
Neurology, 2012. 79(18): p. 1917-26.
[15] Hottinger, A.F. and Y. Khakoo, Update on the management of familial central nervous sys‐
tem tumor syndromes. Curr Neurol Neurosci Rep, 2007. 7(3): p. 200-7.
[16] Serrano, M., G.J. Hannon, and D. Beach, A new regulatory motif in cell-cycle control
causing specific inhibition of cyclin D/CDK4. Nature, 1993. 366(6456): p. 704-7.
[17] Sherr, C.J. and J.M. Roberts, CDK inhibitors: positive and negative regulators of G1-phase
progression. Genes Dev, 1999. 13(12): p. 1501-12.
Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor40
[18] Wong, A.J., et al., Increased expression of the epidermal growth factor receptor gene in ma‐
lignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A,
1987. 84(19): p. 6899-903.
[19] Westermark, B., C.H. Heldin, and M. Nister, Platelet-derived growth factor in human
glioma. Glia, 1995. 15(3): p. 257-63.
[20] Louis, D.N., Molecular pathology of malignant gliomas. Annu Rev Pathol, 2006. 1: p.
97-117.
[21] Gomez-Manzano, C., et al., Characterization of p53 and p21 functional interactions in
glioma cells en route to apoptosis. J Natl Cancer Inst, 1997. 89(14): p. 1036-44.
[22] Leung, S.Y., et al., Chromosomal instability and p53 inactivation are required for genesis of
glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene
mutation. Oncogene, 2000. 19(35): p. 4079-83.
[23] Hamilton, S.R., et al., The molecular basis of Turcot's syndrome. N Engl J Med, 1995.
332(13): p. 839-47.
[24] Ekstrand, A.J., et al., Amplified and rearranged epidermal growth factor receptor genes in
human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-ter‐
minal tails. Proc Natl Acad Sci U S A, 1992. 89(10): p. 4309-13.
[25] Ohgaki, H., et al., Genetic pathways to glioblastoma: a population-based study. Cancer Res,
2004. 64(19): p. 6892-9.
[26] Yamazaki, H., et al., Amplification of the structurally and functionally altered epidermal
growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol, 1988. 8(4): p.
1816-20.
[27] Biernat, W., et al., Predominant expression of mutant EGFR (EGFRvIII) is rare in primary
glioblastomas. Brain Pathol, 2004. 14(2): p. 131-6.
[28] Barker, F.G., 2nd, et al., EGFR overexpression and radiation response in glioblastoma mul‐
tiforme. Int J Radiat Oncol Biol Phys, 2001. 51(2): p. 410-8.
[29] Shinojima, N., et al., Prognostic value of epidermal growth factor receptor in patients with
glioblastoma multiforme. Cancer Res, 2003. 63(20): p. 6962-70.
[30] Haas-Kogan, D.A., et al., Epidermal growth factor receptor, protein kinase B/Akt, and glio‐
ma response to erlotinib. J Natl Cancer Inst, 2005. 97(12): p. 880-7.
[31] van den Bent, M.J., et al., Randomized phase II trial of erlotinib versus temozolomide or car‐
mustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol,
2009. 27(8): p. 1268-74.
[32] Guha, A., et al., Expression of PDGF and PDGF receptors in human astrocytoma operation
specimens supports the existence of an autocrine loop. Int J Cancer, 1995. 60(2): p. 168-73.
[33] Lokker, N.A., et al., Platelet-derived growth factor (PDGF) autocrine signaling regulates
survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and
Systems Biology of Glioblastoma Multiforme
http://dx.doi.org/10.5772/59642
41
PDGF-D ligands may play a role in the development of brain tumors. Cancer Res, 2002.
62(13): p. 3729-35.
[34] Reardon, D.A., et al., Multicentre phase II studies evaluating imatinib plus hydroxyurea in
patients with progressive glioblastoma. Br J Cancer, 2009. 101(12): p. 1995-2004.
[35] Haas-Kogan, D., et al., Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells
due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol, 1998. 8(21): p. 1195-8.
[36] Zhao, J., et al., Signal transduction and metabolic flux of beta-thujaplicin and monoterpene
biosynthesis in elicited Cupressus lusitanica cell cultures. Metab Eng, 2006. 8(1): p. 14-29.
[37] Lemmon, M.A., Membrane recognition by phospholipid-binding domains. Nat Rev Mol
Cell Biol, 2008. 9(2): p. 99-111.
[38] Vivanco, I. and C.L. Sawyers, The phosphatidylinositol 3-Kinase AKT pathway in human
cancer. Nat Rev Cancer, 2002. 2(7): p. 489-501.
[39] Kita, D., et al., PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta
Neuropathol, 2007. 113(3): p. 295-302.
[40] Furnari, F.B., et al., Malignant astrocytic glioma: genetics, biology, and paths to treatment.
Genes Dev, 2007. 21(21): p. 2683-710.
[41] Li, J., et al., PTEN, a putative protein tyrosine phosphatase gene mutated in human brain,
breast, and prostate cancer. Science, 1997. 275(5308): p. 1943-7.
[42] Tohma, Y., et al., PTEN (MMAC1) mutations are frequent in primary glioblastomas (de
novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol, 1998. 57(7): p.
684-9.
[43] Mellinghoff, I.K., et al., Molecular determinants of the response of glioblastomas to EGFR
kinase inhibitors. N Engl J Med, 2005. 353(19): p. 2012-24.
[44] Zinzalla, V., et al., Activation of mTORC2 by association with the ribosome. Cell, 2011.
144(5): p. 757-68.
[45] Laplante, M. and D.M. Sabatini, mTOR signaling in growth control and disease. Cell,
2012. 149(2): p. 274-93.
[46] Zoncu, R., A. Efeyan, and D.M. Sabatini, mTOR: from growth signal integration to can‐
cer, diabetes and ageing. Nat Rev Mol Cell Biol, 2011. 12(1): p. 21-35.
[47] Chang, S.M., et al., Phase II study of CCI-779 in patients with recurrent glioblastoma mul‐
tiforme. Invest New Drugs, 2005. 23(4): p. 357-61.
[48] Galanis, E., et al., Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multi‐
forme: a North Central Cancer Treatment Group Study. J Clin Oncol, 2005. 23(23): p.
5294-304.
Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor42
[49] Hurley, J.B., et al., Homologies between signal transducing G proteins and ras gene prod‐
ucts. Science, 1984. 226(4676): p. 860-2.
[50] Nakada, M., et al., Aberrant signaling pathways in glioma. Cancers (Basel), 2011. 3(3): p.
3242-78.
[51] Holland, E.C., et al., Combined activation of Ras and Akt in neural progenitors induces
glioblastoma formation in mice. Nat Genet, 2000. 25(1): p. 55-7.
[52] Moodie, S.A., et al., Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kin‐
ase kinase. Science, 1993. 260(5114): p. 1658-61.
[53] Thomas, S.M., et al., Ras is essential for nerve growth factor- and phorbol ester-induced ty‐
rosine phosphorylation of MAP kinases. Cell, 1992. 68(6): p. 1031-40.
[54] Krakstad, C. and M. Chekenya, Survival signalling and apoptosis resistance in glioblasto‐
mas: opportunities for targeted therapeutics. Mol Cancer, 2010. 9: p. 135.
[55] Kapoor, G.S. and D.M. O'Rourke, Receptor tyrosine kinase signaling in gliomagenesis:
pathobiology and therapeutic approaches. Cancer Biol Ther, 2003. 2(4): p. 330-42.
[56] Gottfried, O.N., D.H. Viskochil, and W.T. Couldwell, Neurofibromatosis Type 1 and tu‐
morigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus, 2010.
28(1): p. E8.
[57] Verhaak, R.G., et al., Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer
Cell, 2010. 17(1): p. 98-110.
[58] Bogler, O., et al., The p53 gene and its role in human brain tumors. Glia, 1995. 15(3): p.
308-27.
[59] Stott, F.J., et al., The alternative product from the human CDKN2A locus, p14(ARF), partic‐
ipates in a regulatory feedback loop with p53 and MDM2. EMBO J, 1998. 17(17): p.
5001-14.
[60] Haupt, Y., et al., Mdm2 promotes the rapid degradation of p53. Nature, 1997. 387(6630):
p. 296-9.
[61] Kubbutat, M.H., S.N. Jones, and K.H. Vousden, Regulation of p53 stability by Mdm2.
Nature, 1997. 387(6630): p. 299-303.
[62] Zauberman, A., et al., A functional p53-responsive intronic promoter is contained within
the human mdm2 gene. Nucleic Acids Res, 1995. 23(14): p. 2584-92.
[63] Kamijo, T., et al., Functional and physical interactions of the ARF tumor suppressor with
p53 and Mdm2. Proc Natl Acad Sci U S A, 1998. 95(14): p. 8292-7.
[64] Zhang, Y., Y. Xiong, and W.G. Yarbrough, ARF promotes MDM2 degradation and stabil‐
izes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression path‐
ways. Cell, 1998. 92(6): p. 725-34.
Systems Biology of Glioblastoma Multiforme
http://dx.doi.org/10.5772/59642
43
[65] Nakamura, M., et al., p14ARF deletion and methylation in genetic pathways to glioblasto‐
mas. Brain Pathol, 2001. 11(2): p. 159-68.
[66] Solomon, D.A., et al., Conspirators in a capital crime: co-deletion of p18INK4c and
p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme. Cancer Res, 2008. 68(21): p.
8657-60.
[67] Labuhn, M., et al., Quantitative real-time PCR does not show selective targeting of
p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human
primary gliomas. Oncogene, 2001. 20(9): p. 1103-9.
[68] Squatrito, M., et al., Loss of ATM/Chk2/p53 pathway components accelerates tumor devel‐
opment and contributes to radiation resistance in gliomas. Cancer Cell, 2010. 18(6): p.
619-29.
[69] Durocher, D. and S.P. Jackson, DNA-PK, ATM and ATR as sensors of DNA damage: var‐
iations on a theme? Curr Opin Cell Biol, 2001. 13(2): p. 225-31.
[70] Stracker, T.H., T. Usui, and J.H. Petrini, Taking the time to make important decisions: the
checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair
(Amst), 2009. 8(9): p. 1047-54.
[71] Hirao, A., et al., Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telan‐
giectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol,
2002. 22(18): p. 6521-32.
[72] Henson, J.W., et al., The retinoblastoma gene is involved in malignant progression of astro‐
cytomas. Ann Neurol, 1994. 36(5): p. 714-21.
[73] Biernat, W., et al., Alterations of cell cycle regulatory genes in primary (de novo) and secon‐
dary glioblastomas. Acta Neuropathol, 1997. 94(4): p. 303-9.
[74] Lam, P.Y., et al., Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J
Neurosurg, 2000. 14(1): p. 28-32.
[75] Schmidt, E.E., et al., CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in
the majority of glioblastomas. Cancer Res, 1994. 54(24): p. 6321-4.
[76] Hayashi, Y., et al., Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene
deletion in glioblastoma multiforme. Brain Pathol, 1997. 7(3): p. 871-5.
[77] Hegi, M.E., et al., Hemizygous or homozygous deletion of the chromosomal region contain‐
ing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblas‐
tomas. Int J Cancer, 1997. 73(1): p. 57-63.
[78] Abal, M., et al., Molecular pathology of endometrial carcinoma: transcriptional signature in
endometrioid tumors. Histol Histopathol, 2006. 21(2): p. 197-204.
[79] Rahaman, S.O., et al., Inhibition of constitutively active Stat3 suppresses proliferation and
induces apoptosis in glioblastoma multiforme cells. Oncogene, 2002. 21(55): p. 8404-13.
Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor44
[80] Rajan, P. and R.D. McKay, Multiple routes to astrocytic differentiation in the CNS. J Neu‐
rosci, 1998. 18(10): p. 3620-9.
[81] Lin, G.S., et al., STAT3 serine 727 phosphorylation influences clinical outcome in glioblasto‐
ma. Int J Clin Exp Pathol, 2014. 7(6): p. 3141-9.
[82] Ashizawa, T., et al., Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temo‐
zolomide-resistant glioblastoma cell line. Int J Oncol, 2014. 45(1): p. 411-8.
[83] Liang, Q., et al., Inhibition of STAT3 reduces astrocytoma cell invasion and constitutive ac‐
tivation of STAT3 predicts poor prognosis in human astrocytoma. PLoS ONE, 2013. 8(12):
p. e84723.
[84] Smith, D., et al., NF-kappaB controls growth of glioblastomas/astrocytomas. Mol Cell Bio‐
chem, 2008. 307(1-2): p. 141-7.
[85] Romashkova, J.A. and S.S. Makarov, NF-kappaB is a target of AKT in anti-apoptotic
PDGF signalling. Nature, 1999. 401(6748): p. 86-90.
[86] Sanai, N., A. Alvarez-Buylla, and M.S. Berger, Neural stem cells and the origin of glio‐
mas. N Engl J Med, 2005. 353(8): p. 811-22.
[87] Jackson, E.L., et al., PDGFR alpha-positive B cells are neural stem cells in the adult SVZ
that form glioma-like growths in response to increased PDGF signaling. Neuron, 2006.
51(2): p. 187-99.
[88] Artavanis-Tsakonas, S., M.D. Rand, and R.J. Lake, Notch signaling: cell fate control and
signal integration in development. Science, 1999. 284(5415): p. 770-6.
[89] Androutsellis-Theotokis, A., et al., Notch signalling regulates stem cell numbers in vitro
and in vivo. Nature, 2006. 442(7104): p. 823-6.
[90] Lee, J., et al., Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway
inhibits differentiation of glioblastoma-initiating cells. Cancer Cell, 2008. 13(1): p. 69-80.
[91] Kefas, B., et al., The neuronal microRNA miR-326 acts in a feedback loop with notch and
has therapeutic potential against brain tumors. J Neurosci, 2009. 29(48): p. 15161-8.
[92] Guessous, F., et al., microRNA-34a is tumor suppressive in brain tumors and glioma stem
cells. Cell Cycle, 2010. 9(6): p. 1031-6.
[93] Hjelmeland, A.B., et al., Targeting A20 decreases glioma stem cell survival and tumor
growth. PLoS Biol, 2010. 8(2): p. e1000319.
[94] Chuang, Y.Y., et al., Role of synaptojanin 2 in glioma cell migration and invasion. Cancer
Res, 2004. 64(22): p. 8271-5.
[95] Salhia, B., et al., Inhibition of Rho-kinase affects astrocytoma morphology, motility, and in‐
vasion through activation of Rac1. Cancer Res, 2005. 65(19): p. 8792-800.
Systems Biology of Glioblastoma Multiforme
http://dx.doi.org/10.5772/59642
45
[96] Tang, Z., L.M. Araysi, and H.M. Fathallah-Shaykh, c-Src and neural Wiskott-Aldrich
syndrome protein (N-WASP) promote low oxygen-induced accelerated brain invasion by
gliomas. PLoS ONE, 2013. 8(9): p. e75436.
[97] Fathallah-Shaykh, H.M., Logical networks inferred from highly specific discovery of tran‐
scriptionally regulated genes predict protein states in cultured gliomas. Biochem Biophys
Res Comm, 2005. 336: p. 1278-1284.
[98] Carracedo, A., et al., Inhibition of mTORC1 leads to MAPK pathway activation through a
PI3K-dependent feedback loop in human cancer. J Clin Invest, 2008. 118(9): p. 3065-74.
[99] Howell, J.J. and B.D. Manning, mTOR couples cellular nutrient sensing to organismal
metabolic homeostasis. Trends Endocrinol Metab, 2011. 22(3): p. 94-102.
[100] Huang, J. and B.D. Manning, A complex interplay between Akt, TSC2 and the two mTOR
complexes. Biochem Soc Trans, 2009. 37(Pt 1): p. 217-22.
[101] Carracedo, A. and P.P. Pandolfi, The PTEN-PI3K pathway: of feedbacks and cross-talks.
Oncogene, 2008. 27(41): p. 5527-41.
[102] Shah, O.J. and T. Hunter, Turnover of the active fraction of IRS1 involves raptor-mTOR-
and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol
Cell Biol, 2006. 26(17): p. 6425-34.
[103] Harrington, L.S., G.M. Findlay, and R.F. Lamb, Restraining PI3K: mTOR signalling goes
back to the membrane. Trends Biochem Sci, 2005. 30(1): p. 35-42.
[104] Tremblay, F., et al., Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and
obesity-induced insulin resistance. Proc Natl Acad Sci U S A, 2007. 104(35): p. 14056-61.
[105] Manning, B.D., Balancing Akt with S6K: implications for both metabolic diseases and tu‐
morigenesis. J Cell Biol, 2004. 167(3): p. 399-403.
[106] Zhang, H., et al., PDGFRs are critical for PI3K/Akt activation and negatively regulated by
mTOR. J Clin Invest, 2007. 117(3): p. 730-8.
[107] Zhang, H., et al., Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling
through downregulation of PDGFR. J Clin Invest, 2003. 112(8): p. 1223-33.
[108] Costanzo, M., et al., The genetic landscape of a cell. Science, 2010. 327: p. 425-431.
[109] Potter, C.J., L.G. Pedraza, and T. Xu, Akt regulates growth by directly phosphorylating
Tsc2. Nat Cell Biol, 2002. 4(9): p. 658-65.
[110] Inoki, K., et al., TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signal‐
ling. Nat Cell Biol, 2002. 4(9): p. 648-57.
[111] Dan, H.C., et al., Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tu‐
mor suppressor complex by phosphorylation of tuberin. J Biol Chem, 2002. 277(38): p.
35364-70.
Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor46
[112] Sarbassov, D.D., et al., Phosphorylation and regulation of Akt/PKB by the rictor-
mTOR complex. Science, 2005. 307(5712): p. 1098-101.
Systems Biology of Glioblastoma Multiforme
http://dx.doi.org/10.5772/59642
47

